Korean Drugmakers Race to Develop Monthly Obesity Shots

Following the success of Eli Lilly's Mounjaro, Korean drugmakers are intensifying efforts to develop monthly obesity shots, aiming for less frequent injections in the competitive market.

16 May, 00:00 — 16 May, 00:00

Post Share

Sources

Showing 1 of 1 sources

Korea HeraldMostly Factual1h ago

Beyond Mounjaro: Korean drugmakers chase monthly obesity shot

With Eli Lilly’s diabetes and obesity treatment Mounjaro overtaking MSD’s cancer therapy Keytruda as the world’s top-selling drug in the first quarter, Korean drugmakers are focusing on developing monthly obesity shots that involve less frequent injections. Mounjaro and Novo Nordisk’s diabetes and obesity treatment Wegovy currently require weekly injections. Samsung Epis Holdings’ two subsidiaries — biopharmaceutical developer Samsung Bioepis and biotechnology platform developer Epis NexLab — te

By The Korea Herald

Read full article →

PERSPECTA

PERSPECTA

Korean Drugmakers Race to Develop Monthly Obesity Shots

Sources

Beyond Mounjaro: Korean drugmakers chase monthly obesity shot

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

Energy chief probes outages in PH grids

OpenAI Acquires Voice Cloning AI Company Weights.gg

Lagos Olympic City Project Aims to Boost Sports and Housing

PERSPECTA